Yidu Tech (STU:0EL) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0EL Yidu Tech Inc STU:0EL
43 GF Score
Price €0.49
GF Value €0.66
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Yidu Tech Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:0EL
43GF Score
Yidu Tech Inc STU:0EL
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Yidu Tech (STU:0EL) Overvalued in 2026?

Based on GuruFocus' analysis, Yidu Tech stock appears to be undervalued. The current stock price of €0.49 is trading 25.2% below its estimated GF Value™ of €0.66. GuruFocus considers Yidu Tech to be Modestly Undervalued.

Key valuation signals for STU:0EL:

  • Interest Received:
  • GF Value™: €0.66 vs. price of €0.49 (25.2% below fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the STU:0EL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Yidu Tech Business Description

Other Exchanges 02158:Hong Kong0EL:Germany
Address Lincui Xili Phase 3, Building 22, Chaoyang District, Beijing, CHN
Yidu Tech Inc offers healthcare solutions built on big data and artificial intelligence (AI) technologies. The company serves various healthcare industry participants, including hospitals, pharmaceutical, biotech, research institutions, insurance companies, etc. Its operating segments are: Big data platform and solutions, Life sciences solutions, and Health management platform and solutions. The majority of the company's revenue is generated from its Big data platform and solutions segment, which provides data intelligence platforms and data analytics-driven solutions (such as Eywa 5.0, Lingxi Intelligent Management, AI Middleware, etc.) for hospitals, healthcare institutions, regulators, and policymakers. Geographically, the company generates maximum revenue from Mainland China.
43GF Score

Get the complete analysis for STU:0EL

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.49
Price
€0.66
GF Value